Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 6 of 6 matching drugs for ALDH2 — including drugs targeting any of its 7 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
chemotherapy, disulfiram, gemcitabine hydrochloride, laboratory biomarker analysis ALDH2 Direct 1
disulfiram, copper gluconate, surgery, radiation, temozolomide ALDH2 Direct 1
disulfiram, copper, alkylating agents ALDH2 Direct 1
temozolomide, aprepitant, minocycline, disulfiram, celecoxib, sertraline, captopril, itraconazole, ritonavir, auranofin ALDH2 Direct 1
temozolomide, disulfiram, copper gluconate ALDH2 Direct 1
disulfiram ALDH2 Direct yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.